<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086693</url>
  </required_header>
  <id_info>
    <org_study_id>2019-188</org_study_id>
    <nct_id>NCT04086693</nct_id>
  </id_info>
  <brief_title>Peripheral Intravenous Catheter Securement With Tissue Adhesive</brief_title>
  <official_title>Peripheral Intravenous Catheter Securement With Tissue Adhesive Compared to Conventional Dressing: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will compare survival of peripheral intravenous (IV) catheters for&#xD;
      patients with a standard IV site dressing alone to patients with standard IV dressing plus&#xD;
      Adhezion Biomedical SecurePortIV Catheter Securement Adhesive. Emergency room patients who&#xD;
      already have IVs may be considered for inclusion. Eligible patients will be approached and,&#xD;
      if they are interested in participating, their informed consent will be obtained.&#xD;
      Participation will continue for up to 7 days. During this time, the patient will experience:&#xD;
&#xD;
        -  Assessment of their currently placed peripheral IV catheter, to assess if it is&#xD;
           functioning&#xD;
&#xD;
        -  Assignment to one of two study groups (standard IV dressing or standard IV dressing plus&#xD;
           Adhezion Biomedical SecurePortIV Catheter Securement Adhesive). This is called&#xD;
           randomization and group assignment is by chance, like the flip of a coin&#xD;
&#xD;
        -  Daily assessment of the IV catheter and site for complications (such as infection or&#xD;
           phlebitis), removal, and medications being administered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients admitted from the Emergency Department (ED) to a progressive floor, or patients&#xD;
      admitted from ED to any floor type with express approval from the Principal Investigator are&#xD;
      eligible participants. Research staff will approach patients admitted to the progressive&#xD;
      floors (or other floors when identified by PI) based on screening of the electronic medical&#xD;
      record. These patients are approached by research staff when physically in the emergency&#xD;
      department waiting for a room assignment. If the patient agrees to participate in the trial,&#xD;
      the study subject will approached for consent by the research staff. Research staff will&#xD;
      confirm functionality of the existing peripheral IV previously placed by ED staff. The&#xD;
      assessment will include observing for blood return into the tubing upon aspiration and/or&#xD;
      unobstructed flush with a minimum of 1-2 ml of normal saline. Staff will also observe the&#xD;
      site for any signs of redness or tenderness. A tourniquet may be applied as needed. If the&#xD;
      patient is actively receiving an infusion, the drip will briefly be halted to evaluate for&#xD;
      functionality. Functionality will be assessed with the existing dressing in place. If the&#xD;
      catheter is functional and free of any signs of complications, study subjects will be&#xD;
      randomized by a computer generated 1:1 envelope system to either the control group:&#xD;
      polyurethane dressing + clear tape or the experimental group: polyurethane dressing + clear&#xD;
      tape + tissue adhesive. The tissue adhesive is not standard of care at Beaumont. For the&#xD;
      control group, the polyurethane dressing will be gently removed. Dressing will be removed&#xD;
      carefully to minimize any potential dislodgments or skin injury. The site will be evaluated&#xD;
      for oozing or blood and as needed cleaned with sterile gauze. Once the site is completely&#xD;
      dry, a new polyurethane dressing will be applied and reinforced with tape in a standard&#xD;
      fashion. Once securement is complete, functionality will be reassessed per protocol above.&#xD;
      For the experimental group, the existing securement will be gently removed. There are not&#xD;
      special steps required for removing the dressing with the tissue adhesive. The IV catheter is&#xD;
      secured and the dressing is removed gently. The site will be evaluated for oozing or blood&#xD;
      and as needed cleaned with sterile gauze. Once the site is completely dry, the tissue&#xD;
      adhesive will be applied. A new standard polyurethane dressing will be applied and tape will&#xD;
      be applied per the standard approach. Once securement is complete, functionality will be&#xD;
      reassessed. The time of the new dressing application will be noted as time zero. Catheter&#xD;
      dwell time will begin at this point. Additional data variables collected at the initial&#xD;
      assessment include: demographics such as age, sex, international normalized ratio (INR) &gt;1.5,&#xD;
      platelets &lt; 50, insertion site details, hours from insertion to recruitment, inserter&#xD;
      credentials.&#xD;
&#xD;
      Follow-up Assessment:&#xD;
&#xD;
      After initial assessment, the catheter will be assessed by the research team every 24 hours&#xD;
      as long as the patient is hospitalized up to 7 days or 168 hours. At each follow up interval&#xD;
      the researcher notes the date /time of evaluation and assesses for any signs and symptoms of&#xD;
      complications and functionality of the device. A catheter is functional if the IV flushes&#xD;
      without resistance. Complications include infiltration, phlebitis, dislodgement, oozing&#xD;
      fluid/blood, purulent drainage, or occlusion. Catheters will be assessed daily for signs and&#xD;
      symptoms of complications. Any signs or symptoms of complications or lack of functionality&#xD;
      will be reported to the patient's primary care team so that management of the IV catheter can&#xD;
      be addressed. If the catheter was identified to have any signs or symptoms of complications&#xD;
      during follow-up assessment the date and time of observation of the complication will be&#xD;
      documented in the data collection tool and the primary team will be notified of the&#xD;
      complication. If the catheter was removed prior to the follow-up assessment then the IV&#xD;
      removal time and the reason for removal will be obtained through chart review. For all&#xD;
      catheters removed due to a complication, re-insertion attempt data will be tracked through&#xD;
      the medical record in the nursing section for venous lines and need for reinsertion of the IV&#xD;
      or escalation to a midline, peripherally inserted central catheter (PICC), or central venous&#xD;
      catheter (CVC) will be noted. If the patient is discharged prior to the time of follow-up&#xD;
      assessment then the time of discharge will be documented and the IV will be presumed&#xD;
      functional until time of discharge unless otherwise noted in the chart.&#xD;
&#xD;
      The medication administration record will be queried for all medications given through each&#xD;
      catheter with specific attention to antibiotics and anticoagulants. Vesicants/irritants that&#xD;
      are generally given via central line or considered caustic to the vessel will be noted in&#xD;
      both groups. Number of doses will be recorded. Additional data gathered by research staff on&#xD;
      follow-up evaluation includes: dwell time in days/hours, hospital length of stay, and number&#xD;
      of peripheral IVs for duration of stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Actual">October 10, 2020</completion_date>
  <primary_completion_date type="Actual">October 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled, parallel assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IV Catheter Survival</measure>
    <time_frame>7 days or discharge, whichever occurs sooner</time_frame>
    <description>Number of participants with all-cause functional failure of the catheter. Failure is defined by loss of patency (resistance to flush with minimum 1-2 ml normal saline, or lack of blood return to tubing on aspiration) or presence of complications requiring removal (any level of pain or tenderness, changes in skin color (blanching or erythema), changes in skin temperature (hot or cold), edema, induration, leakage of fluid or purulent discharge from the puncture site, or other dysfunction). Function is assessed daily by research staff.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Catheter Survival Duration</measure>
    <time_frame>7 days or until discharge, whichever occurs sooner</time_frame>
    <description>Mean catheter survival duration in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific IV Failure</measure>
    <time_frame>7 days or until discharge, whichever occurs sooner</time_frame>
    <description>Number of participants with IV catheter failures by specific cause, including infiltration, phlebitis, dislodgment, leaking, infection, and occlusion. IV failure is assessed daily by research staff and by chart review, post patient discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Vascular Access Devices</condition>
  <arm_group>
    <arm_group_label>Standard IV dressing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyurethane dressing with clear tape</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard IV dressing plus Adhezion SecurePortIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard IV dressing</intervention_name>
    <description>Polyurethane and clear tape dressing used to secure peripheral IV</description>
    <arm_group_label>Standard IV dressing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard IV dressing plus a tissue adhesive peripheral IV securement device</intervention_name>
    <description>Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV</description>
    <arm_group_label>Standard IV dressing plus Adhezion SecurePortIV</arm_group_label>
    <other_name>Adhezion SecurePortIV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Greater or equal to 18 years of age&#xD;
&#xD;
          2. Admission from the Emergency Department (ED) to a progressive floor, or Admission from&#xD;
             ED to any floor type with express approval from the Principal Investigator&#xD;
&#xD;
          3. IV placement in the antecubital fossa, forearm, wrist or hand&#xD;
&#xD;
          4. IV placement in the ED&#xD;
&#xD;
          5. Enrollment within 8 hours of IV insertion&#xD;
&#xD;
          6. 18 or 20 gauge 1.16 inch IV catheter&#xD;
&#xD;
          7. Expected hospital admission &gt;48 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with ultrasound-guided IV insertions&#xD;
&#xD;
          2. Alternate site of cannulation&#xD;
&#xD;
          3. Voluntary withdrawal&#xD;
&#xD;
          4. Patients with a non-standard polyurethane dressing&#xD;
&#xD;
          5. Known allergy to cyanoacrylate or formaldehyde&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Bahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beaumont Health System</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <results_first_submitted>January 6, 2021</results_first_submitted>
  <results_first_submitted_qc>January 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2021</results_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Amit Bahl</investigator_full_name>
    <investigator_title>Director Emergency Medicine Ultrasound</investigator_title>
  </responsible_party>
  <keyword>intravenous access</keyword>
  <keyword>vascular access</keyword>
  <keyword>IV survival</keyword>
  <keyword>IV catheter complication</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04086693/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>350</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard IV Dressing</title>
          <description>Polyurethane dressing with clear tape&#xD;
Standard IV dressing: Polyurethane and clear tape dressing used to secure peripheral IV</description>
        </group>
        <group group_id="P2">
          <title>Standard IV Dressing Plus Adhezion SecurePortIV</title>
          <description>Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).&#xD;
Standard IV dressing plus a tissue adhesive peripheral IV securement device: Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard IV Dressing</title>
          <description>Polyurethane dressing with clear tape&#xD;
Standard IV dressing: Polyurethane and clear tape dressing used to secure peripheral IV</description>
        </group>
        <group group_id="B2">
          <title>Standard IV Dressing Plus Adhezion SecurePortIV</title>
          <description>Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).&#xD;
Standard IV dressing plus a tissue adhesive peripheral IV securement device: Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="174"/>
            <count group_id="B2" value="171"/>
            <count group_id="B3" value="345"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="171"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="15.3"/>
                    <measurement group_id="B2" value="68.8" spread="15.4"/>
                    <measurement group_id="B3" value="68.4" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="174"/>
                    <count group_id="B2" value="171"/>
                    <count group_id="B3" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>IV Catheter Survival</title>
        <description>Number of participants with all-cause functional failure of the catheter. Failure is defined by loss of patency (resistance to flush with minimum 1-2 ml normal saline, or lack of blood return to tubing on aspiration) or presence of complications requiring removal (any level of pain or tenderness, changes in skin color (blanching or erythema), changes in skin temperature (hot or cold), edema, induration, leakage of fluid or purulent discharge from the puncture site, or other dysfunction). Function is assessed daily by research staff.</description>
        <time_frame>7 days or discharge, whichever occurs sooner</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard IV Dressing</title>
            <description>Polyurethane dressing with clear tape&#xD;
Standard IV dressing: Polyurethane and clear tape dressing used to secure peripheral IV</description>
          </group>
          <group group_id="O2">
            <title>Standard IV Dressing Plus Adhezion SecurePortIV</title>
            <description>Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).&#xD;
Standard IV dressing plus a tissue adhesive peripheral IV securement device: Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV</description>
          </group>
        </group_list>
        <measure>
          <title>IV Catheter Survival</title>
          <description>Number of participants with all-cause functional failure of the catheter. Failure is defined by loss of patency (resistance to flush with minimum 1-2 ml normal saline, or lack of blood return to tubing on aspiration) or presence of complications requiring removal (any level of pain or tenderness, changes in skin color (blanching or erythema), changes in skin temperature (hot or cold), edema, induration, leakage of fluid or purulent discharge from the puncture site, or other dysfunction). Function is assessed daily by research staff.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Catheter Survival Duration</title>
        <description>Mean catheter survival duration in days</description>
        <time_frame>7 days or until discharge, whichever occurs sooner</time_frame>
        <population>Numbers of participants reflect those fulfilling 48 hour dwell per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Standard IV Dressing</title>
            <description>Polyurethane dressing with clear tape&#xD;
Standard IV dressing: Polyurethane and clear tape dressing used to secure peripheral IV</description>
          </group>
          <group group_id="O2">
            <title>Standard IV Dressing Plus Adhezion SecurePortIV</title>
            <description>Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).&#xD;
Standard IV dressing plus a tissue adhesive peripheral IV securement device: Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Catheter Survival Duration</title>
          <description>Mean catheter survival duration in days</description>
          <population>Numbers of participants reflect those fulfilling 48 hour dwell per protocol</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O2" value="5.97" lower_limit="0" upper_limit="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific IV Failure</title>
        <description>Number of participants with IV catheter failures by specific cause, including infiltration, phlebitis, dislodgment, leaking, infection, and occlusion. IV failure is assessed daily by research staff and by chart review, post patient discharge</description>
        <time_frame>7 days or until discharge, whichever occurs sooner</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard IV Dressing</title>
            <description>Polyurethane dressing with clear tape&#xD;
Standard IV dressing: Polyurethane and clear tape dressing used to secure peripheral IV</description>
          </group>
          <group group_id="O2">
            <title>Standard IV Dressing Plus Adhezion SecurePortIV</title>
            <description>Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).&#xD;
Standard IV dressing plus a tissue adhesive peripheral IV securement device: Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV</description>
          </group>
        </group_list>
        <measure>
          <title>Cause-specific IV Failure</title>
          <description>Number of participants with IV catheter failures by specific cause, including infiltration, phlebitis, dislodgment, leaking, infection, and occlusion. IV failure is assessed daily by research staff and by chart review, post patient discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Infiltration</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Phlebitis</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dislodgement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Leaking</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Occlusion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death of Participant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Completion of Therapy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected on each patient from IV insertion until IV removal for a maximum of 7 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard IV Dressing</title>
          <description>Polyurethane dressing with clear tape&#xD;
Standard IV dressing: Polyurethane and clear tape dressing used to secure peripheral IV</description>
        </group>
        <group group_id="E2">
          <title>Standard IV Dressing Plus Adhezion SecurePortIV</title>
          <description>Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).&#xD;
Standard IV dressing plus a tissue adhesive peripheral IV securement device: Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amit Bahl, MD</name_or_title>
      <organization>Beaumont Health</organization>
      <phone>248-551-1792</phone>
      <email>Amit.Bahl@beaumont.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

